85 results
8-K
EX-99.1
BEAM
Beam Therapeutics Inc
7 May 24
Beam Therapeutics Reports Pipeline Updates and First Quarter 2024 Financial Results
7:09am
, without limitation, risks and uncertainties related to: our ability to successfully achieve the benefits of our portfolio prioritization and strategic
S-3ASR
BEAM
Beam Therapeutics Inc
27 Feb 24
Automatic shelf registration
6:10pm
personnel;
the strategic and other potential benefits of our acquisition of any additional technologies;
our ability to achieve the expected benefits … stockholder; or
the receipt by the interested stockholder of the benefit of any loss, advances, guarantees, pledges or other financial benefits by or through
S-3ASR
EX-4.4
9qs7rn191pal 7a
27 Feb 24
Automatic shelf registration
6:10pm
S-3ASR
EX-1.2
3zrvoz1h04js0
27 Feb 24
Automatic shelf registration
6:10pm
S-3ASR
EX-4.3
tr6p2
27 Feb 24
Automatic shelf registration
6:10pm
8-K
EX-99.1
d012o5q
27 Feb 24
Beam Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Reiterates Anticipated Milestones
6:43am
8-K
EX-99.1
0rvj5z3o5gt
8 Jan 24
Results of Operations and Financial Condition
6:55am
8-K
EX-99.2
uio8jgfd5
8 Jan 24
Results of Operations and Financial Condition
6:55am
8-K
s29gs t0jz81tki
8 Jan 24
Results of Operations and Financial Condition
6:55am
8-K
EX-99.1
nlll571 kxo
14 Dec 23
Beam Therapeutics Appoints Biotech Executive Christi Shaw to its Board of Directors
4:05pm
8-K
EX-99.1
rgn79rz01e0acj5
8 Nov 23
Beam Therapeutics Reports Pipeline and Business Updates and Third Quarter 2023 Financial Results
7:00am
8-K
yzipcsh6h 8yb555
19 Oct 23
Cost Associated with Exit or Disposal Activities
8:50am
8-K
EX-99.1
6o35mvgv
19 Oct 23
Cost Associated with Exit or Disposal Activities
8:50am
8-K
EX-99.2
8ed8g0
19 Oct 23
Cost Associated with Exit or Disposal Activities
8:50am